Check Point Software Technologies beat fourth-quarter profit expectations on Thursday, with revenue exceeding $2.5 billion in 2024, and forecast profit growth of up to 11% in 2025.
On Friday, the FDA approved Checkpoint Therapeutics, Inc.’s (NASDAQ:CKPT) Unloxcyt (cosibelimab-ipdl) for metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not ...